Eric Duncavage, MD

Medical School Department Pathology and Immunology
Eric Duncavage

Researcher Background

Primary Academic Title

Professor, Pathology & Immunology

Education

  • 1994: Tennessee Honors Diploma: Brentwood High School, Brentwood, TN
  • 1998: Cum Laude, Majors in Physics and Chemistry: Vanderbilt University, Nashville, TN
  • 2004: Medical Degree: University of Tennessee College of Medicine, Memphis, TN
  • 2008: Resident Physician, Anatomic and Clinical Pathology: Washington University/Barnes-Jewish Hospital, St. Louis, MO
  • 2009: Molecular Genetic Pathology Fellow: Washington University, St. Louis, MO
  • 2010: Hematopathology Fellow: University of Utah/ARUP lab, Salt Lake City, UT

Research & Selected Publications

Research Interest

My primary research interests are the development of methods to detect and monitor small clonal populations in cancer, including minimal residual disease monitoring. My clinical interests are the diagnosis and pathogenesis of myelodysplastic syndrome and other myeloid malignancies as well as the incorporation of sequencing based diagnostics into routine clinical practice.

Research Publications

Analytical validation of a scrape-free multitarget stool RNA test for colorectal cancer screening.
Authors:

Barnell EK, Kruse K, Wurtzler EM, one or more additional authors omitted Duncavage EJ

Journal & Year:

Pract Lab Med • 2025

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.
Authors:

Gurnari C, Robin M, Adès L, one or more additional authors omitted Duncavage EJ, one or more additional authors omitted Cazzola M

Journal & Year:

Blood • 2025

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcino…
Authors:

Hiken J, Earls J, Flanagan KC, one or more additional authors omitted Duncavage EJ

Journal & Year:

BMC Cancer • 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Walter MJ

Journal & Year:

Leukemia • 2025

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.
Authors:

Flanagan KC, Earls J, Hiken J, one or more additional authors omitted Duncavage EJ

Journal & Year:

J Immunother Cancer • 2024

Analytical Validation of the Multitarget Stool RNA Test for Colorectal Cancer Screening.
Authors:

Barnell EK, Land J, Kruse K, one or more additional authors omitted Duncavage EJ

Journal & Year:

J Mol Diagn • 2024

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Authors:

Flanagan KC, Earls J, Schillebeeckx I, one or more additional authors omitted Duncavage EJ

Journal & Year:

J Cancer Res Clin Oncol • 2023